



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

## Kanuma

### Procedural steps taken and scientific information after the authorisation\*

\*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

Application number	Scope	Opinion/ Notification <sup>1</sup> issued on	Commission Decision Issued <sup>2</sup> / amended on	Product Information affected <sup>3</sup>	Summary
Variation type IB /	C.1 Change(s) in the summary of product	24/03/2026		SmPC and PL	

<sup>1</sup> Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

<sup>2</sup> A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<sup>3</sup> SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



EMA/VR/0000326194	<p>characteristics, labelling or package leaflet intended to implement the outcome of a Union referral procedure - C.1.z Other variation - Accepted</p> <p>C.I.z – to update section 10 of the SmPC and section 6 of the Package Leaflet with a minor correction to EMA website address. In addition, the Package Leaflet sections 2 and 3 have been aligned with QRD v.10.4. Contact details of the local representatives for Malta, Spain and Ireland were updated in section 6 of the Package Leaflet. Local representative for United Kingdom (Northern Ireland) has been removed, in line with QRD v.10.4. Finally, linguistic amendments, wording improvements, editorial updates, typographical corrections, formatting updates were implemented in the Product Information text for EU languages to align with English Product Information text.</p>				
Variation type IA / EMA/VR/0000319646	<p>This was an application for a group of variations.</p> <p>A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active</p>	22/12/2025			

	<p>substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted</p> <p>A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted</p> <p>A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted</p>				
<p>Variation type IA_IN / EMA/VR/0000314792</p>	<p>B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted</p>	<p>02/12/2025</p>			

<p>Variation type IB / EMA/VR/0000296278</p>	<p>This was an application for a group of variations.</p> <p>B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted</p> <p>B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted</p>	<p>02/10/2025</p>			
<p>Variation type IA / EMA/VR/0000269359</p>	<p>A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted</p>	<p>06/05/2025</p>			